Asset
Pilavapadin
Lexicon Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06203002 | phase2 | completed | 2023-11-29 | 2025-01-14 | Lexicon Pharmaceuticals | A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) |
| NCT04662281 | phase2 | completed | 2020-12-10 | 2022-11-18 | Lexicon Pharmaceuticals | Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia |
| NCT04455633 | phase2 | completed | 2020-09-03 | 2022-05-23 | Lexicon Pharmaceuticals | Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain |
FDA applications (0)
This company has no applications containing this asset.